Broadly neutralizing single-domain antibody targeting the spike NTD displays therapeutic efficacy against diverse SARS-CoV-2 variants
Year: 2026
Type: article
Abstract: The continuous evolution of SARS-CoV-2 virus has led to the emergence of multiple Omicron descendants resistant to previously approved therapeutic antibodies. Therefore, cross-reactive antibodies to conserved neutralizing epitopes are urgently needed to protect immunocompromised patients and individuals at high risk of severe COVID-19. Here we report the characterization of 1p2B5, a single-domain antibody targeting N-terminal domain (NTD) of SARS-CoV-2 S protein. 1p2B5 exerts broad neutralizing activity against diverse SARS-CoV-2 variants. The Fc-fused form of the antibody demonstrates enhanced neutralizing potency in vitro , inhibiting both the earliest and currently circulating subvariants with nanomolar activity. Systemic therapeutic administration of 1p2B5-Fc at a dose of 1 mg/kg protects Syrian hamsters and hACE2-transgenic mice from challenge with evolutionarily distant SARS-CoV-2 variants. Our findings highlight the potential of NTD-specific monoclonal antibodies for prophylaxis and therapeutic intervention.
Source: Frontiers in Immunology
Authors: Anastasia I. Korobkova, Irina A. Favorskaya, Inna V. Shuliakova, Anna A. Iliukhina, Daria M. Grousova, Irina A. Alekseeva, Ekaterina I. Ryabova, Artem A. Derkaev, Valentin V. Azizyan, Ilya D. Zorkov, Alina S. Dzharullaeva, Amir I. Tukhvatulin, Ilias B. Esmagambetov, Vladimir V. Prokofiev, Daria V. Voronina, Olga V. Zubkova, Dmitry V. Shcheblyakov, Denis Y. Logunov
Institution: Ministry of Health of the Russian Federation
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7140143940